Next-Generation Multitarget Stool DNA vs Fecal Immunochemical Test in Colorectal Cancer Screening
2024

Next-Generation Stool DNA vs Fecal Immunochemical Test in Colorectal Cancer Screening

Sample size: 7190 publication Evidence: moderate

Author Information

Author(s): Seum Teresa MSc, Niedermaier Tobias PhD, Heisser Thomas PhD, Hoffmeister Michael PhD, Brenner Hermann MD MPH

Primary Institution: German Cancer Research Center (DKFZ), Heidelberg, Germany

Hypothesis

Can lowering the positivity threshold of a commercial fecal immunochemical test (FIT) yield similar diagnostic performance to a next-generation multitarget stool DNA test (NG-MSDT)?

Conclusion

Lowering the positivity threshold of a high-quality FIT may provide a more economical way to increase sensitivity in noninvasive colorectal cancer screening.

Supporting Evidence

  • Lowering the cutoff of the FIT to 11.7 μg/g yielded comparable specificity to the NG-MSDT.
  • At a cutoff of 10 μg/g, the FIT achieved a sensitivity of 96.5% for CRC.
  • The study included 7190 participants, making it a substantial analysis.

Takeaway

This study shows that a regular stool test can work just as well as a newer, more expensive DNA test for checking for colon cancer if we adjust the test settings.

Methodology

The study compared the diagnostic performance of a commercial FIT and a next-generation multitarget stool DNA test using data from a large screening colonoscopy cohort.

Limitations

The study is an indirect comparison and may not account for all variables affecting test performance.

Participant Demographics

Participants were primarily from Germany, with a mean age of 61.3 years and a sex distribution of 51.6% women.

Digital Object Identifier (DOI)

10.1001/jamainternmed.2024.6149

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication